Trial Profile
A Study to Evaluate the Effects of Dabigatran and Rivaroxaban on Platelet Reactivity and Inflammatory Markers in Patients With Non Valvular Atrial Fibrillation (AF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Jun 2016
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Pharmacodynamics; Therapeutic Use
- 10 Jun 2016 New trial record